ArticleAmino acids2026
Reprogramming parasitic signatures into anticancer peptide candidates: in silico discovery of Leishmania major-derived peptides.
Article in Amino acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to computationally identify and prioritize anticancer peptide (ACP) candidate sequences derived from the Leishmania major proteins KMP11 and GP63 using an integrated bioinformatics framework that incorporates peptide design, safety assessment, multi-criteria decision-making, and membrane-oriented evaluation. Amino acid sequences of KMP11 and GP63 were obtained from the NCBI database. Peptide fragments ranging from 5 to 25 residues were computationally generated and initially screened for anticancer potential using AntiCP 2.0 and MLACP prediction tools. Candidate peptides were subsequently subjected to systematic amino acid substitutions followed by iterative re-evaluation to optimize predicted anticancer properties. Toxicity, allergenicity, and antigenicity were assessed using TOXINPRED2, ALGPRED2, and VAXIJEN2, respectively. Peptides meeting safety and functional criteria were prioritized using the Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS). Structural modeling, exploratory molecular docking, and membrane interaction analyses were then performed to provide comparative mechanistic insights into membrane association and potential receptor accessibility, rather than to predict specific target binding. Reference datasets of experimentally validated ACPs and non-ACPs were compiled, and motif analysis using MERCI identified sequence patterns associated with anticancer activity, with enriched motifs most frequently observed in the 12-13 residue range. Following iterative screening and safety evaluation, subsets of peptides derived from KMP11 and GP63 were identified as non-toxic and non-allergenic according to in silico prediction tools. These peptides were subsequently prioritized using the TOPSIS multi-criteria decision-making model. The top-ranked candidates were further subjected to exploratory molecular docking against selected cancer-associated receptors and coarse-grained membrane interaction analysis to provide comparative mechanistic context regarding membrane interaction propensity and potential receptor accessibility. Based on integrated computational scoring, ten peptides were prioritized as candidate sequences for further experimental validation. This study demonstrates the feasibility of computationally deriving and prioritizing anticancer peptide candidates from L. major proteins KMP11 and GP63. The proposed framework provides a structured, hypothesis-generating strategy for ACP candidate prioritization, emphasizing comparative evaluation rather than direct prediction of therapeutic efficacy or specific molecular targets. By leveraging evolutionary and physicochemical features associated with host-pathogen interactions, this approach enables systematic exploration of parasite-derived peptide sequence space. Experimental validation will be essential to determine the biological activity, selectivity, and translational relevance of the identified candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.